Lung volume reduction: surgery versus endobronchial valves.

IF 2.3 Q2 RESPIRATORY SYSTEM Breathe Pub Date : 2024-12-10 eCollection Date: 2024-10-01 DOI:10.1183/20734735.0107-2024
Laurens J Ceulemans, Dorina Esendagli, Giuseppe Cardillo, Marcello Migliore
{"title":"Lung volume reduction: surgery <i>versus</i> endobronchial valves.","authors":"Laurens J Ceulemans, Dorina Esendagli, Giuseppe Cardillo, Marcello Migliore","doi":"10.1183/20734735.0107-2024","DOIUrl":null,"url":null,"abstract":"<p><p>Volume reduction is a disease-modifying treatment that aims to reshape the diseased lung towards a more normal total lung capacity by removing severely damaged and overinflated lung parenchyma. It is an effective therapeutic strategy in well-selected patients, resulting in improvements in exercise tolerance, lung function, quality of life and survival. The most widespread strategies for volume reduction are either video-assisted thoracoscopic surgery or bronchoscopic lung volume reduction. It is crucial to decide which approach would be more suitable for specific patients, as this is related to the outcome of the procedure. Factors like emphysema distribution on computed tomography, the presence or absence of collateral ventilation, the patient's pulmonary function tests, a history of other comorbidities and previous interventions might all influence the choice of procedure. It is crucial that this decision is taken by a multidisciplinary expert team to have the best outcome and fewer complications.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240107"},"PeriodicalIF":2.3000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629166/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breathe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/20734735.0107-2024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Volume reduction is a disease-modifying treatment that aims to reshape the diseased lung towards a more normal total lung capacity by removing severely damaged and overinflated lung parenchyma. It is an effective therapeutic strategy in well-selected patients, resulting in improvements in exercise tolerance, lung function, quality of life and survival. The most widespread strategies for volume reduction are either video-assisted thoracoscopic surgery or bronchoscopic lung volume reduction. It is crucial to decide which approach would be more suitable for specific patients, as this is related to the outcome of the procedure. Factors like emphysema distribution on computed tomography, the presence or absence of collateral ventilation, the patient's pulmonary function tests, a history of other comorbidities and previous interventions might all influence the choice of procedure. It is crucial that this decision is taken by a multidisciplinary expert team to have the best outcome and fewer complications.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肺减容:手术还是支气管内瓣膜。
体积缩小是一种疾病修饰治疗,旨在通过去除严重受损和过度膨胀的肺实质,重塑患病肺,使其达到更正常的肺总容量。在精心挑选的患者中,它是一种有效的治疗策略,可以改善运动耐量、肺功能、生活质量和生存率。最广泛的减容策略是电视胸腔镜手术或支气管镜肺减容。决定哪种方法更适合特定的患者是至关重要的,因为这关系到手术的结果。计算机断层扫描上的肺气肿分布、有无侧支通气、患者肺功能检查、其他合并症史和既往干预等因素都可能影响手术的选择。这是至关重要的,这个决定是由一个多学科的专家团队做出的,以获得最好的结果和更少的并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Breathe
Breathe RESPIRATORY SYSTEM-
CiteScore
2.90
自引率
5.00%
发文量
51
审稿时长
12 weeks
期刊最新文献
A 69-year-old man with generalised lymphadenopathy, glandular swelling and pleural effusion. Cardiopulmonary disease. Developments in the field of respiratory nursing in Türkiye. Extracorporeal membrane oxygenation for adults with respiratory failure secondary to cardiorespiratory disease: evolving indications and clinical practice. From basic scientific research to the development of new drugs for pulmonary arterial hypertension: insights from activin-targeting agents.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1